Comments

AbbVie Analyst Ratings

ABBVNYSE

Logo brought to you by Benzinga Data

Trade with Public

$222.49

-1.49-0.67%

Last update: Dec 12, 10:41 AM

Overview News Earnings Options Guidance Dividends

Analyst Ratings

Insider Trades Short Interest Government Trades Stock Report

Consensus Rating¹

Overweight

Highest Price Target¹

$289.00

Lowest Price Target¹

$190.00

Consensus Price Target¹

$233.85

AbbVie Analyst Ratings and Price Targets | NYSE:ABBV | Benzinga

AbbVie Inc has a consensus price target of $233.85 based on the ratings of 28 analysts. The high is $289 issued by Piper Sandler on November 5, 2025. The low is $190 issued by UBS on February 3, 2025. The 3 most-recent analyst ratings were released by HSBC, UBS, and Piper Sandler on December 10, 2025, November 7, 2025, and November 5, 2025, respectively. With an average price target of $258 between HSBC, UBS, and Piper Sandler, there's an implied 15.96% upside for AbbVie Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Aug

Sep

Oct

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

HSBC

UBS

Piper Sandler

Citigroup

JP Morgan

¹calculated from analyst ratings

Analyst Ratings for AbbVie

					Get Alert
Dec 10, 2025	19.11%	Rajesh KumarHSBC 54%	225 265	Previous Hold Current Buy	Get Alert
Nov 7, 2025	-1.12%	Ashwani VermaUBS 69%	195 220	Previous Neutral Current Neutral	Get Alert
Nov 5, 2025	29.9%	David AmsellemPiper Sandler 79%	284 289	Previous Overweight Current Overweight	Get Alert
Nov 3, 2025	5.63%	Geoff MeachamCitigroup 72%	235 240	Previous Neutral Current Neutral	Get Alert
Nov 3, 2025	16.86%	Chris SchottJP Morgan 65%	250 260	Previous Overweight Current Overweight	Get Alert
Oct 20, 2025	8.77%	Vamil DivanGuggenheim 79%	227 242	Previous Buy Current Buy	Get Alert
Oct 17, 2025	12.37%	Gary NachmanRaymond James 62%	236 250	Previous Outperform Current Outperform	Get Alert
Oct 10, 2025	27.65%	Christopher RaymondPiper Sandler 58%	231 284	Previous Overweight Current Overweight	Get Alert
Oct 9, 2025	12.37%	Carter GouldCantor Fitzgerald 63%	245 250	Previous Overweight Current Overweight	Get Alert
Oct 3, 2025	12.82%	Geoff MeachamB of A Securities 72%	220 251	Previous Neutral Current Neutral	Get Alert
Oct 1, 2025	—	Rajesh KumarHSBC 54%	—	Previous Buy Current Hold	Get Alert
Sep 22, 2025	-0.22%	Gavin Clark-GartnerEvercore ISI Group 47%	207 222	Previous Outperform Current Outperform	Get Alert
Sep 17, 2025	21.36%	Luisa HectorBerenberg 54%	170 270	Previous Hold Current Buy	Get Alert
Sep 16, 2025	5.63%	Chris SchottJP Morgan 65%	200 235	Previous Overweight Current Overweight	Get Alert
Sep 15, 2025	10.12%	Carter GouldCantor Fitzgerald 63%	215 245	Previous Overweight Current Overweight	Get Alert
Sep 12, 2025	16.86%	Mohit BansalWells Fargo 68%	240 260	Previous Overweight Current Overweight	Get Alert
Sep 12, 2025	7.87%	Evan David SeigermanBMO Capital 54%	215 240	Previous Outperform Current Outperform	Get Alert
Aug 13, 2025	-3.36%	Carter GouldCantor Fitzgerald 63%	210 215	Previous Overweight Current Overweight	Get Alert
Aug 12, 2025	3.83%	David AmsellemPiper Sandler 79%	231	Previous Current Overweight	Get Alert
Aug 1, 2025	-6.96%	Gavin Clark-GartnerEvercore ISI Group 47%	205 207	Previous Outperform Current Outperform	Get Alert
Aug 1, 2025	2.03%	Vamil DivanGuggenheim 79%	216 227	Previous Buy Current Buy	Get Alert
Aug 1, 2025	14.61%	Terence FlynnMorgan Stanley 69%	250 255	Previous Overweight Current Overweight	Get Alert
Aug 1, 2025	6.07%	Gary NachmanRaymond James 62%	227 236	Previous Outperform Current Outperform	Get Alert
May 14, 2025	-7.86%	Geoff MeachamCitigroup 72%	205 210	Previous Buy Current Neutral	Get Alert
Apr 29, 2025	-2.91%	Vamil DivanGuggenheim 79%	214 216	Previous Buy Current Buy	Get Alert
Apr 28, 2025	-8.31%	Tim AndersonB of A Securities 66%	200 204	Previous Neutral Current Neutral	Get Alert
Apr 28, 2025	2.03%	Gary NachmanRaymond James 62%	220 227	Previous Outperform Current Outperform	Get Alert
Apr 28, 2025	-7.86%	Gavin Clark-GartnerEvercore ISI Group 47%	204 205	Previous Outperform Current Outperform	Get Alert
Apr 28, 2025	12.37%	Terence FlynnMorgan Stanley 69%	241 250	Previous Overweight Current Overweight	Get Alert
Apr 22, 2025	-5.61%	Carter GouldCantor Fitzgerald 63%	210	Previous Initiates Current Overweight	Get Alert
Apr 21, 2025	-10.11%	Tim AndersonB of A Securities 66%	200 223	Previous Neutral Current Neutral	Get Alert
Apr 17, 2025	-3.81%	Vamil DivanGuggenheim 79%	214 214	Previous Buy Current Buy	Get Alert
Apr 11, 2025	-5.61%	Geoff MeachamCitigroup 72%	210 215	Previous Buy Current Buy	Get Alert
Apr 9, 2025	8.32%	Terence FlynnMorgan Stanley 69%	239 241	Previous Overweight Current Overweight	Get Alert
Apr 8, 2025	-12.8%	Asad Haider Goldman Sachs 62%	194	Previous Current Neutral	Get Alert
Mar 5, 2025	7.87%	Mohit BansalWells Fargo 68%	210 240	Previous Overweight Current Overweight	Get Alert
Mar 4, 2025	0.23%	Tim AndersonB of A Securities 66%	200 223	Previous Neutral Current Neutral	Get Alert
Feb 3, 2025	-3.36%	Geoff MeachamCitigroup 72%	205 215	Previous Buy Current Buy	Get Alert
Feb 3, 2025	-2.47%	Srikripa DevarakondaTruist Securities 70%	211 217	Previous Buy Current Buy	Get Alert
Feb 3, 2025	-14.6%	Navin JacobUBS 65%	181 190	Previous Neutral Current Neutral	Get Alert
Feb 3, 2025	-5.61%	Mohit BansalWells Fargo 68%	195 210	Previous Overweight Current Overweight	Get Alert
Feb 3, 2025	7.42%	Terence FlynnMorgan Stanley 69%	224 239	Previous Overweight Current Overweight	Get Alert
Feb 3, 2025	-1.12%	Gary NachmanRaymond James 62%	218 220	Previous Outperform Current Outperform	Get Alert
Feb 3, 2025	-3.81%	Vamil DivanGuggenheim 79%	212 214	Previous Buy Current Buy	Get Alert
Feb 3, 2025	-3.36%	Evan David SeigermanBMO Capital 54%	208 215	Previous Outperform Current Outperform	Get Alert
Jan 28, 2025	-7.86%	Geoff MeachamCitigroup 72%	205 215	Previous Buy Current Buy	Get Alert
Jan 27, 2025	2.03%	Christopher RaymondPiper Sandler 58%	220 227	Previous Overweight Current Overweight	Get Alert
Jan 17, 2025	-4.71%	Vamil DivanGuggenheim 79%	212 221	Previous Buy Current Buy	Get Alert
Jan 8, 2025	-5.16%	Srikripa DevarakondaTruist Securities 70%	211 215	Previous Buy Current Buy	Get Alert
Dec 17, 2024	-1.12%	Christopher RaymondPiper Sandler 58%	212 220	Previous Overweight Current Overweight	Get Alert
Dec 10, 2024	-14.15%	Tim AndersonB of A Securities 66%	191	Previous Current Neutral	Get Alert
Nov 22, 2024	-7.41%	David RisingerLeerink Partners 71%	206	Previous Market Perform Current Outperform	Get Alert
Nov 18, 2024	-12.35%	Mohit BansalWells Fargo 68%	195 205	Previous Overweight Current Overweight	Get Alert
Nov 15, 2024	-7.86%	Alexandria HammondWolfe Research 62%	205	Previous Initiates Current Outperform	Get Alert
Nov 13, 2024	-10.11%	Chris SchottJP Morgan 65%	200 210	Previous Overweight Current Overweight	Get Alert
Nov 12, 2024	-18.65%	Navin JacobUBS 65%	181 200	Previous Neutral Current Neutral	Get Alert
Nov 12, 2024	-3.36%	Geoff MeachamCitigroup 72%	215 226	Previous Buy Current Buy	Get Alert
Nov 12, 2024	-6.51%	Evan David SeigermanBMO Capital 54%	208 228	Previous Outperform Current Outperform	Get Alert
Nov 12, 2024	0.68%	Terence FlynnMorgan Stanley 69%	224 231	Previous Overweight Current Overweight	Get Alert
Nov 6, 2024	-0.67%	Vamil DivanGuggenheim 79%	212 221	Previous Buy Current Buy	Get Alert
Nov 4, 2024	—	David ToungArgus Research 68%	—	Previous Hold Current Buy	Get Alert
Oct 31, 2024	7.87%	Louise ChenCantor Fitzgerald 61%	200 240	Previous Overweight Current Overweight	Get Alert
Oct 31, 2024	-5.61%	Geoff MeachamB of A Securities 72%	195 210	Previous Neutral Current Neutral	Get Alert
Oct 31, 2024	2.48%	Evan David SeigermanBMO Capital 54%	220 228	Previous Outperform Current Outperform	Get Alert
Oct 31, 2024	1.58%	Geoff MeachamCitigroup 72%	215 226	Previous Buy Current Buy	Get Alert
Oct 31, 2024	-10.11%	Navin JacobUBS 65%	195 200	Previous Neutral Current Neutral	Get Alert
Oct 31, 2024	3.83%	Terence FlynnMorgan Stanley 69%	218 231	Previous Overweight Current Overweight	Get Alert
Oct 25, 2024	-3.36%	Andrew BaumCitigroup 72%	170 215	Previous Buy Current Buy	Get Alert
Oct 18, 2024	-12.35%	Geoff MeachamB of A Securities 72%	185 195	Previous Neutral Current Neutral	Get Alert
Oct 17, 2024	-1.12%	Evan David SeigermanBMO Capital 54%	214 220	Previous Outperform Current Outperform	Get Alert
Oct 17, 2024	-8.76%	Aaron GalBernstein 54%	203	Previous Initiates Current Market Perform	Get Alert
Oct 10, 2024	-3.36%	Srikripa DevarakondaTruist Securities 70%	210 215	Previous Buy Current Buy	Get Alert
Oct 9, 2024	-12.35%	Navin JacobUBS 65%	185 195	Previous Neutral Current Neutral	Get Alert
Oct 7, 2024	-4.71%	Carter GouldBarclays 63%	200 212	Previous Overweight Current Overweight	Get Alert
Oct 7, 2024	1.13%	Steve ScalaTD Cowen 67%	195 225	Previous Buy Current Buy	Get Alert
Aug 23, 2024	-6.06%	Christopher RaymondPiper Sandler 58%	196 209	Previous Overweight Current Overweight	Get Alert
Aug 12, 2024	-2.02%	Terence FlynnMorgan Stanley 69%	211 218	Previous Overweight Current Overweight	Get Alert
Aug 5, 2024	-10.11%	Louise ChenCantor Fitzgerald 61%	200 200	Previous Overweight Current Overweight	Get Alert
Jul 26, 2024	-16.85%	Navin JacobUBS 65%	172 185	Previous Neutral Current Neutral	Get Alert
Jul 26, 2024	-10.11%	Louise ChenCantor Fitzgerald 61%	200 200	Previous Overweight Current Overweight	Get Alert
Jul 26, 2024	-5.61%	Robyn KarnauskasTruist Securities 54%	195 210	Previous Buy Current Buy	Get Alert
Jul 26, 2024	-7.86%	Mohit BansalWells Fargo 68%	200 205	Previous Overweight Current Overweight	Get Alert
Jul 26, 2024	-10.11%	Carter GouldBarclays 63%	187 200	Previous Overweight Current Overweight	Get Alert
Jul 25, 2024	-5.61%	Chris SchottJP Morgan 65%	190 210	Previous Overweight Current Overweight	Get Alert
Jul 19, 2024	-3.81%	Evan David SeigermanBMO Capital 54%	180 214	Previous Outperform Current Outperform	Get Alert
Jul 11, 2024	-11.9%	Terence FlynnMorgan Stanley 69%	191 196	Previous Overweight Current Overweight	Get Alert
Jul 9, 2024	-10.11%	Louise ChenCantor Fitzgerald 61%	200 200	Previous Overweight Current Overweight	Get Alert
Jul 2, 2024	-14.6%	Christopher RaymondPiper Sandler 58%	190 190	Previous Overweight Current Overweight	Get Alert
Jun 20, 2024	-10.11%	Louise ChenCantor Fitzgerald 61%	200 200	Previous Overweight Current Overweight	Get Alert
Jun 18, 2024	-14.6%	Christopher RaymondPiper Sandler 58%	185 190	Previous Overweight Current Overweight	Get Alert
Jun 5, 2024	-16.85%	Rajesh KumarHSBC 54%	185	Previous Hold Current Buy	Get Alert
May 17, 2024	-10.11%	Louise ChenCantor Fitzgerald 61%	200	Previous Initiates Current Overweight	Get Alert
Apr 29, 2024	-14.15%	Terence FlynnMorgan Stanley 69%	191 196	Previous Overweight Current Overweight	Get Alert
Apr 29, 2024	-15.95%	Carter GouldBarclays 63%	187 195	Previous Overweight Current Overweight	Get Alert
Apr 29, 2024	-19.1%	Evan David SeigermanBMO Capital 54%	180 195	Previous Outperform Current Outperform	Get Alert
Mar 27, 2024	-12.35%	Carter GouldBarclays 63%	185 195	Previous Overweight Current Overweight	Get Alert
Mar 22, 2024	-14.6%	Vamil DivanGuggenheim 79%	188 190	Previous Buy Current Buy	Get Alert
Feb 6, 2024	-22.69%	Navin JacobUBS 65%	165 172	Previous Neutral Current Neutral	Get Alert
Feb 6, 2024	-15.05%	Gary NachmanRaymond James 62%	181 189	Previous Current Outperform	Get Alert
Feb 6, 2024	-12.35%	Robyn KarnauskasTruist Securities 54%	180 195	Previous Buy Current Buy	Get Alert

FAQ

What is the target price for AbbVie (ABBV) stock?

The latest price target for AbbVie (NYSE:ABBV) was reported by HSBC on December 10, 2025. The analyst firm set a price target for $265.00 expecting ABBV to rise to within 12 months (a possible 19.11% upside). 50 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for AbbVie (ABBV)?

The latest analyst rating for AbbVie (NYSE:ABBV) was provided by HSBC, and AbbVie upgraded their buy rating.

When was the last upgrade for AbbVie (ABBV)?

The last upgrade for AbbVie Inc happened on December 10, 2025 when HSBC raised their price target to $265. HSBC previously had a hold for AbbVie Inc.

When was the last downgrade for AbbVie (ABBV)?

The last downgrade for AbbVie Inc happened on October 1, 2025 when HSBC changed their price target from N/A to N/A for AbbVie Inc.

When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on December 10, 2025 so you should expect the next rating to be made available sometime around December 10, 2026.

Is the Analyst Rating AbbVie (ABBV) correct?

While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a upgraded with a price target of $225.00 to $265.00. The current price AbbVie (ABBV) is trading at is $222.49, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.